Wayne Gulliver
Overview
Explore the profile of Wayne Gulliver including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J, et al.
Nat Commun
. 2025 Feb;
16(1):2051.
PMID: 40021644
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is...
2.
Alhusayen R, Dienes S, Lam M, Alavi A, Alikhan A, Aleshin M, et al.
J Am Acad Dermatol
. 2024 Dec;
PMID: 39725212
Background: Hidradenitis suppurativa (HS) affects different patient populations that require unique considerations in their management. However, no HS guidelines for these populations exist. Objective: To provide evidence-based consensus recommendations for...
3.
Muntyanu A, Milan R, Kaouache M, Ringuet J, Gulliver W, Pivneva I, et al.
Am J Clin Dermatol
. 2024 Mar;
25(3):497-508.
PMID: 38498268
Background: Psoriasis is a major global health burden affecting ~ 60 million people worldwide. Existing studies on psoriasis focused on individual-level health behaviors (e.g. diet, alcohol consumption, smoking, exercise) and...
4.
Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J, et al.
medRxiv
. 2023 Oct;
PMID: 37873414
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is...
5.
Badaiki W, Pyper E, Lester K, Skeard J, Penney M, Shin J, et al.
Int J Popul Data Sci
. 2023 Aug;
7(1):1690.
PMID: 37650031
The Janssen and Newfoundland and Labrador Health Innovation Partnership (JANL-HIP) was established to carry out Real-World Evidence (RWE) projects to generate evidence about disease pathways, healthcare delivery, the effects of...
6.
Lagace F, Noorah B, Conte S, Mija L, Chang J, Cattelan L, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568569
Background: The incidence of cutaneous melanoma (CM) is increasing at an alarming rate in Canada and elsewhere around the world. Significant regional differences in CM incidence have been identified in...
7.
Bui A, Kumar S, Liu J, Orcales F, Gulliver S, Tsoi L, et al.
Front Genet
. 2023 Jun;
14:1141010.
PMID: 37323656
Psoriasis is an immune-mediated inflammatory skin disease typically characterized by erythematous and scaly plaques. It affects 3% of the Newfoundland population while only affecting 1.7% of the general Canadian population....
8.
Poelman S, Gulliver W
J Cutan Med Surg
. 2023 May;
27(4):402-403.
PMID: 37158501
No abstract available.
9.
Karagaiah P, Daveluy S, Ortega-Loayza A, Gulliver W, Szepietowski J, Grabbe S, et al.
J Drugs Dermatol
. 2023 Apr;
22(4):369-374.
PMID: 37026880
Hidradenitis suppurativa (HS), a chronic inflammatory disorder of the apocrine-bearing skin, presents with deep seated inflamed nodules, abscesses, draining sinus tracts, and scarring with a profound impact on quality of...
10.
van Straalen K, Tzellos T, Alavi A, Benhadou F, Cuenca-Barrales C, Daxhelet M, et al.
Dermatology
. 2023 Jan;
239(3):362-367.
PMID: 36630943
Background: Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 (IHS4-55) score. It was validated in datasets of adalimumab and placebo-treated HS...